BIOAGE LABS, INC. Revenue
BIOAGE LABS, INC. (BIOA) reported Revenue of $2.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- BIOAGE LABS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $2.45M, a 1.62% increase year-over-year.
- BIOAGE LABS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $2.77M, a 91.04% increase year-over-year.
- BIOAGE LABS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $3.08M.
- BIOAGE LABS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $2.05M.
- BIOAGE LABS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $8.99M.
- BIOAGE LABS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.45M 10-Q · filed 2026-08-05 | $5.22M 10-Q · filed 2026-08-05 | $8.30M derived: sum of 3 quarters · filed 2026-08-05 | $10.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.77M 10-Q · filed 2026-05-08 | $5.85M derived: sum of 2 quarters · filed 2026-05-08 | $7.90M derived: sum of 3 quarters · filed 2026-05-08 | $10.32M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $5.13M derived: sum of 2 quarters · filed 2026-03-24 | $7.54M derived: sum of 3 quarters · filed 2026-08-05 | $8.99M 10-K · filed 2026-03-24 |
| 2025-09-30 | $2.05M 10-Q · filed 2025-11-06 | $4.47M derived: sum of 2 quarters · filed 2026-08-05 | $5.92M 10-Q · filed 2025-11-06 | $5.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.41M 10-Q · filed 2026-08-05 | $3.86M 10-Q · filed 2026-08-05 | $3.86M derived: sum of 3 quarters · filed 2026-08-05 | $3.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.45M 10-Q · filed 2026-05-08 | $1.45M derived: sum of 2 quarters · filed 2026-05-08 | $1.45M derived: sum of 3 quarters · filed 2026-05-08 | $1.45M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $0.00 derived: sum of 2 quarters · filed 2026-03-24 | $0.00 derived: sum of 3 quarters · filed 2026-03-24 | $0.00 10-K · filed 2026-03-24 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |